Beigene Sees Unusually Large Options Volume (BGNE)

Beigene Ltd (NASDAQ:BGNE) was the target of some unusual options trading activity on Tuesday. Investors acquired 2,178 call options on the stock. This is an increase of approximately 3,933% compared to the typical volume of 54 call options.

NASDAQ:BGNE opened at $126.69 on Wednesday. Beigene has a 12 month low of $77.54 and a 12 month high of $220.10. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.14 and a quick ratio of 8.10. The stock has a market capitalization of $9.26 billion, a PE ratio of -56.81 and a beta of 0.67.

Beigene (NASDAQ:BGNE) last posted its earnings results on Thursday, August 9th. The company reported ($2.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.12) by ($0.80). The company had revenue of $52.80 million during the quarter, compared to analysts’ expectations of $22.53 million. Beigene had a negative return on equity of 24.14% and a negative net margin of 75.19%. The company’s revenue for the quarter was up 5279999900.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.52) earnings per share. As a group, research analysts forecast that Beigene will post -10.82 earnings per share for the current year.

In other news, CMO Jane Huang sold 2,911 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $174.60, for a total value of $508,260.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Amy C. Peterson sold 5,769 shares of the firm’s stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $169.12, for a total transaction of $975,653.28. Following the completion of the sale, the chief marketing officer now directly owns 4,661 shares of the company’s stock, valued at $788,268.32. The disclosure for this sale can be found here. Insiders have sold a total of 14,129 shares of company stock valued at $2,389,512 in the last three months. 14.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Beigene by 43.9% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 8,521 shares of the company’s stock worth $1,310,000 after acquiring an additional 2,599 shares in the last quarter. Baker BROS. Advisors LP increased its stake in shares of Beigene by 105.2% in the 2nd quarter. Baker BROS. Advisors LP now owns 11,959,824 shares of the company’s stock worth $1,838,584,000 after acquiring an additional 6,130,395 shares in the last quarter. MYDA Advisors LLC bought a new position in shares of Beigene in the 2nd quarter worth about $384,000. Morgan Stanley increased its stake in shares of Beigene by 39.6% in the 2nd quarter. Morgan Stanley now owns 500,476 shares of the company’s stock worth $76,939,000 after acquiring an additional 142,078 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Beigene in the 2nd quarter worth about $754,000. Institutional investors own 77.87% of the company’s stock.

Several equities research analysts have recently commented on the stock. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Sunday. BidaskClub cut shares of Beigene from a “sell” rating to a “strong sell” rating in a research report on Monday. Zacks Investment Research raised shares of Beigene from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. ValuEngine raised shares of Beigene from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Leerink Swann assumed coverage on shares of Beigene in a research report on Monday, September 24th. They issued an “outperform” rating and a $215.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $186.34.

About Beigene

BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Further Reading: Investing in Growth Stocks

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply